Althea offers cGMP plasmid production, protein production, formulation and filling services. Plasmid DNA and protein production are offered using both Althea’s industry-leading manufacturing process as well as client developed processes. A range of options are available for formulation and filling services ranging from semi- automated to fully- automated processes for vials and syringes. Althea is focused on offering highly responsive customer service, flexible scheduling, and rapid turnaround times to meet the requirements of both early stage clinical programs and commercial programs alike.
François Ferré, Ph.D.
Co-President and Co-Chief Executive Officer, Director
Co-President and Co-Chief Executive Officer, Director
Dr. Ferré is a founder, co-President and co-Chief Executive Officer of Althea Technologies, Inc, a San Diego company that provides services and technologies to streamline drug development. He has over twenty years of experience in cancer research and HIV clinical development. Dr. Ferré has held management positions at Cytometrics and The Immune Response Corporation. Dr. Ferré is a leader in gene quantification and biomarker development with over fifteen years of experience in the field. He has published several authoritative reviews on the topic of gene quantification, co-edited a bestseller book on PCR with Dr. Kary Mullis and Dr. Richard Gibbs, and edited a book on the topic of gene quantification. Dr. Ferré received his Ph.D. in Molecular Oncology from the Pasteur Institute in Lille, France and did his post-doctoral training at the University of California, San Diego. Dr. Ferré was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category.
James Glavin
Director
Director
Mr. Glavin has been a member of the Board of Directors since December 1997. Mr. Glavin is Chairman of the Board of Directors of The Immune Response Corporation, where he previously served as President and Chief Executive Officer. Prior to joining The Immune Response Corporation, he served as Chairman of the Board of Directors of Smith Laboratories, Inc., a medical products company and as Acting President and Chief Executive Officer of that company. Mr. Glavin currently serves as a director of Inhale Therapeutics Systems, Inc., AVANIR Pharmaceuticals and the Meridian Fund. He has a degree in Economics from Harvard University and an M.B.A from Harvard Business School.
Deval A. Lashkari, Ph.D
Director
Director
Dr. Lashkari joined Althea Technologies’ Board of Directors in 2006. He has been actively involved in developing and commercializing novel technologies in the life sciences area over the past 16 years. Dr. Lashkari gained corporate and business development experience through senior management positions in a number of biotechnology companies. In addition, he was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he was Director of Product Development and with Operon Technologies, which was acquired by Qiagen. He received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.
J. Matthew Mackowski
Director
Director
Mr. Mackowski began serving on Althea Technologies’ Board in 2006. He has been a healthcare-focused venture capital investor since 1980. He began his venture capital career with Citicorp Venture Capital, where he was VP and a member of the investment executive committee. Mr. Mackowski later joined Robertson, Stephens and Co. and was partner and Chairman of the Venture Capital Group. In 1991 he formed Mackowski and Shepler, an investment partnership focused on developing life science and medical technology companies and the predecessor to Telegraph Hill Partners (THP) where he serves as Chairman and Managing Director. He received a BA from Duke University and an MBA from The Wharton School.
Magda Marquet, Ph.D.
Co-President and Co-Chief Executive Officer, Director
Co-President and Co-Chief Executive Officer, Director
Dr. Marquet is a founder, co-President and co-Chief Executive Officer of Althea Technologies, Inc., a San Diego company that provides services and technologies to streamline drug development. Dr. Marquet has over twenty years of experience in the biotechnology industry in the United States and Europe. She was formerly Executive Director of Pharmaceutical Development at Vical Incorporated, where she patented several novel methods for the production of clinical grade DNA for use in gene therapy and DNA vaccines. Prior to joining Vical, Dr. Marquet held management positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. Dr. Marquet is a member of the board of Directors of BIOCOM and UCSD Athena. Dr. Marquet holds a Ph.D in Biochemical Engineering from the University of Toulouse/INSA, France. Dr. Marquet has received numerous prizes throughout her career. She was the winner of the 2005 E&Y Entrepreneur of the Year award in the Life Sciences category, the 2005 UCSD Athena Pinnacle award in Technology and the 2004 Women Who Mean Business award from the San Diego Business Journal.
Althea Technologies
A leading provider of contract services to
the pharmaceutical and biotechnology industries
11040 Roselle Street | San Diego, CA 92121-1205
Toll-free 1-888-4ALTHEA
info@altheatech.com